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Abstract: We report our experience in 4 patients with chronic myeloid leukemia (CML) who had discontinued imatinib as a result of 
adverse events and had switched to dasatinib. The chronic phase (n 2) and accelerated phase (n 2) CML patients received dasatinib 
at starting dose of 100 and 140 mg once daily, respectively. Reappearance of hematological toxicity was observed in 3 patients and 
pancreatitis in one patient. Treatment was given at a lower dose and patients were followed. The median follow-up was 13 months and 
the median dose of dasatinib until achievement of complete cytogenetic remission (CCyR) was 60 mg daily (range = 20 to 120 mg). 
All four patients had achieved CCyR at a median of 4 months (range = 3 to 5 months) and among them, three had also achieved major 
molecular remission. We conclude that low-dose dasatinib therapy in intolerant patients appears safe and efficacious and may be tried 
before drug discontinuation.
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Introduction
Chronic myeloid leukemia (CML) is a myeloprolif-
erative disorder of blood stem cells.1 The causative 
molecular defect is the BCR-ABL protein, which 
is encoded by the Philadelphia chromosome (Ph).2 
This genetic anomaly arises from an exchange of 
genetic material between chromosomes 9 and 22, 
which results in the fusion of the breakpoint cluster 
region (BCR) and the Abelson leukemia virus (ABL) 
proto-oncogene.3,4  The  resulting  gene  encodes  a 
constitutively active protein kinase that activates a 
number of proteins involved in cell-cycle regulation 
that hasten cell division and affect DNA repair.5–8 
Imatinib, also known as Gleevec® (Novartis, Basel, 
Switzerland),  is  a  selective  inhibitor  of  not  only 
ABL but also Kit and PDGFR kinases, and exerts 
significant antileukemic activity in the majority of 
CML patients.
According  to  the  current  National  Comprehen-
sive Cancer Network (NCCN) guidelines9 and the 
European LeukemiaNet (ELN) recommendations,10 
a response outcome to imatinib therapy is classified 
as optimal, suboptimal, and failure based on the level 
of response achieved at various time points through-
out the course of treatment using specific hemato-
logic,  cytogenetic  and  molecular  criteria.  Optimal 
responses  proposed  by  the  NCCN  closely  corre-
sponding to the ELN recommendations and defined 
as the achievement of a CCyR after 12 months of 
imatinib at 400 mg daily. In patients with suboptimal 
responses to first-line imatinib, the use of high-dose 
(600 or 800 mg/day) is recommended as an alternative 
therapeutic option by both the ELN and the NCCN. 
Failure  to  achieve  any  cytogenetic  response  from 
standard-dose imatinib after 6 months of therapy or 
major cytogenetic response and a CCyR after 12 and 
18 months of   therapy, respectively, are considered 
treatment failure by the NCCN. In such cases, it is 
recommended that treatment should be changed for 
a second-  generation tyrosine kinase inhibitor (TKI). 
These criteria became particularly important as sev-
eral  kinase  targeted  therapies  with  long  half-lives 
were developed for the treatment of patients who fail 
or are intolerant to imatinib therapy.
According  to  the  most  recent  results  from  the 
International  Randomized  Study  of  Interferon 
  versus  STI571  (IRIS)  trial,  the  estimated  overall 
survival for patients still on imatinib was 85% at 
8 years, or 93% when only CML-related deaths or 
deaths prior to stem cell transplant were included. 
A total of 92% of the patients were free of disease 
progression.  Among  those  who  achieved  CCyR, 
only 3% progressed during the 8-year follow-up.11 
  Nevertheless, of the 259 patients receiving imatinib 
as front-line therapy who had treatment discontinua-
tion, 30 (5.4%) and 77 (13.9%) patients stopped their 
therapy because of intolerance or unsatisfactory ther-
apeutic effect, respectively. The inability of patients 
to tolerate treatment and the emergence of BCR-ABL 
mutations that reduced the binding affinity of ima-
tinib prompted pharmaceutical research that led to 
the discovery of several similarly effective, targeted, 
second generation TKIs such as nilotinib (Tasigna, 
AMN107, Novartis, Basel, Switzerland) and dasat-
inib (SPRYCEL; Bristol-Myers Squibb, New York, 
NY).12–14 Evidence from an in vitro study has indi-
cated  that  nilotinib  is  20  times  more  potent  than 
imatinib against cells expressing the wild-type BCR-
ABL.15 Dasatinib is a multi-targeted kinase inhibitor 
that is structurally unrelated to imatinib and is able to 
bind and inhibit both the active and inactive confor-
mations of ABL, resulting in 100- to 300-fold higher 
activity than imatinib for unmutated BCR-ABL, and 
greater inhibition against mutants with high levels 
of imatinib resistance (except for T315I and rela-
tive insensitivity to F317L).15–17 Dasatinib is gener-
ally well tolerated. However, adverse events (AEs) 
associated  with  its  use,  such  as  pleural  effusions, 
hemorrhage, and febrile neutropenia have been fre-
quently reported in the advanced stage of the dis-
ease (reviewed by Wong18). The NCCN guidelines9 
recommend that at the onset of grade 3/4 thrombo-
cytopenia  (platelet  count  ,50,000/mm),  therapy 
with dasatinib should be held. Once the toxicity has 
resolved  (platelet  count  $50,000/mm),  dasatinib 
should be resumed at original starting dose if recov-
ery occurs within 7 days or reduced one dose level 
if platelet count decreased to ,25,000/mm for more 
than 7 days.
Attempts  to  identify  the  optimum  and  effective 
dose  of  dasatinib  continue  and  include  modifica-
tion of scheduling, management of toxicity and dose 
optimization.  To  determine  the  optimum  adminis-
tration  schedule,  the  efficacy,  response  and  toler-
ability of dasatinib has been investigated in several 
  clinical  trials.  It  is  now  apparent  that  a  scheduled Efficacy of dasatinib low doses in CML intolerant patients
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once daily   starting dose of 100 mg offers an improved 
safety profile and shows similar efficacy for patients 
with chronic phase CML (CP CML) compared to a 
70 mg twice daily dose.19–21 The recommended dos-
age schedule for patients in the advanced phase of 
the disease is 140 mg once daily.22,23 However, some 
intolerant  patients  may  require  a  dose  adjustment 
from 140 to 100 mg/day or from 100 to 80 mg/day to 
continue treatment and thus maintain control of their 
disease. Even at a dose of 80 mg/day, some patients 
require  further  dose  reduction  due  to  substantial 
toxicities.  Because  of  the  clinical  difficulty  posed 
by this subgroup, we report the effects of an unusu-
ally low dosage of dasatinib during the treatment of 
four patients (2 in chronic phase and 2 in accelerated 
phase) with proven efficacy almost identical to that 
seen with conventional dosage.
Case one
A  31-year-old  man  was  admitted  to  our  depart-
ment  in  March  2008  with  leukocytosis  (WBC 
88.900/mm³) and splenomegaly of CML. The patient 
was treated with imatinib mesylate at 400 mg/day in 
July 2008. One month after starting the therapy, the 
patient developed a grade (G) 4 thrombocytopenia 
(8.000/mm³ platelets) with epistaxis and needed a 
platelet   transfusion. The patient had a therapy break 
of 4 months. In October 2008, after resolution of 
thrombocytopenia to the G1 level, he was restarted 
on a reduced imatinib dose of 300 mg per day, but 
therapy was again discontinued for thrombocytope-
nia G3 (26.000/mm³ platelets). In February 2009, 
because of severe intolerance to imatinib, dasatinib 
was started at a dose of 100 mg/day. After 2 weeks 
of treatment under this therapy, the patient devel-
oped  a  G4  thrombocytopenia.  As  a  result,  treat-
ment was suspended until (March 2009) recovery 
to G1 (78.000/mm³) and then resumed at a dose of 
80  mg/day.  However,  the  patient  experienced  the 
same side effects one week after restarting dasat-
inib. The dose was then decreased to 50 mg/day with 
gradual  increase  of  platelets.  In  June  2009,  after 
4 months of treatment, the patient achieved a CCyR. 
The patient continued the same dasatinib dose and 
in July 2009, the platelet count reached 130.000/
mm³ and molecular analysis showed a BCR-ABL/
BCR ratio of 0.01% indicating that the patient had 
achieved a major molecular response (MMR).
Case two
A 46-year-old male was admitted to our department 
in July 2008 with CP CML. The patient received 
imatinib  at  400  mg/day  in  September  2008. This 
patient had two breaks in his imatinib therapy due 
to the recurring of G 3 thrombocytopenia. After the 
second  break,  the  patient  progressed  to AP  CML 
without evidence of mutations in the ABL kinase 
domain. In March 2009, dasatinib was prescribed 
to this patient at 140 mg/day and after four weeks 
of  therapy,  the  patient  developed  G3  thrombocy-
topenia,  after  which  we  decided  to  maintain  the 
therapy at a lower dose of 70 mg/day. In June 2009, 
after three months of treatment, the patient reached 
a CCyR and his thrombocytopenia improved to G1. 
To achieve MMR, we decided to increase the thera-
peutic dose to 80 mg/day in May 2010. By August 
2010, on his last evaluation, this patient’s BCR-ABL/
BCR ratio showed 0.8%.
Case three
A  69-year-old  male  was  admitted  to  our  depart-
ment in March 2009 with a history of CML, first 
diagnosed  in  August  2007  in  Japan.  Six  months 
before the referral, he complained of fatigue, weight 
loss  and  splenomegaly.  The  patient  had  received 
hydroxyurea to control his leukocytosis. A diagno-
sis of AP CML was confirmed with the appearance 
of additional chromosomal aberrations besides the 
Ph chromosome (47XY, +8, t(9,22), add(13)(q33) 
in 20/20 metaphase analyzed) and, in March 2009, 
imatinib was initiated at a daily dose of 600 mg. 
After  1  month,  the  patient  experienced  G3  neu-
tropenia  (700/mm3)  and  G2  thrombocytopenia 
(62.000/mm3).  The  patient  continued  imatinib  at 
the  same  dose  with  300  µg  granulocyte-colony-
stimulating  factor  (G-CSF)  added  simultaneously 
every week to stimulate myelopoiesis. In October 
2009, the patient experienced G3 thrombocytope-
nia  (41.000/mm³)  and  his  BCR-ABL/BCR  ratio 
was 7.68% without any cytogenetic response after 
6  months  of  therapy. At  this  time,  sequencing  of 
the BCR-ABL kinase domain revealed no evidence 
of mutations in the ABL kinase domain. Based on 
these results, the patient was, therefore, considered 
resistant to imatinib and, in November 2009, was 
placed on dasatinib at a daily dose of 140 mg. After 
the first 3 weeks of treatment, dasatinib was reduced Serpa et al
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to  100  mg/day  because  of  the  occurrence  of  G2 
thrombocytopenia (61.000/mm³). Two weeks later, 
his platelet count dropped to 50.000/mm³. At this 
time, dasatinib was lowered to a dose of 70 mg in 
an attempt to maintain a stable platelet count. How-
ever, after another 2 weeks, in   January 2010, the 
patient  developed  G3  neutropenia  (900/mm³)  and 
his platelet count dropped to 26.000/mm³. At this 
time, the patient`s BCR-ABL/BCR ratio was 9.87%. 
As dasatinib was the only option for the treatment 
of this patient’s disease, it was again reduced to a 
dose of 50 mg/day with G-CSF. In February 2010, 
the patient’s BCR-ABL/BCR ratio was decreased to 
0.81% and his platelet numbers started to increase 
gradually. As a result, G-CSF was stopped and the 
patient continued dasatinib at the same dose. Five 
months after initiation of dasatinib, in April 2010, 
cytogenetic analysis revealed a CCyR and complete 
disappearance  of  the  initially  detected  additional 
chromosomal aberrations. In May 2010, dasatinib 
was increased to 60 mg once daily to achieve MMR 
and no toxicity was noted on follow-up examination. 
One month later, in June 2010, the patient achieved 
MMR, with a transcript ratio of 0.01%.
Case four
The patient, a 58-year-old man, was presented to our 
hospital in March 2009 with a clinical history of rheu-
matoid arthritis, hypertension, gastritis and chronic 
renal failure and undergoing conservative therapy. 
At presentation, a routine blood count showed leu-
kocytosis with a left shift and physical examination 
revealed no splenomegaly. A diagnosis of CP CML 
was  made  after  further  laboratory  studies  and,  in 
April 2009, imatinib was initiated at a daily dose of 
400 mg. After a one month, despite a complete hema-
tological response, the patient`s pancreatic enzymes 
elevated to G1 and then gradually increased in sever-
ity to G4 in May 2009. This result led to immedi-
ate treatment suspension. After a one month period 
of interruption, imatinib was resumed at the same 
dose.  However,  the  patient  experienced  the  same 
side  effects  again  and  treatment  was  permanently 
discontinued. One month later, the patient’s pancre-
atic enzyme values returned to normal but he lost his 
hematologic response. At that time,   dasatinib was ini-
tiated at a dose of 100 mg/day. During   follow-up, the 
patient had two breaks in the dasatinib therapy at a 
daily dose of 100 mg and 40 mg because of recurring 
G2  and  G4  pancreatitis,  respectively. An  abdomi-
nal computed tomography scan did not reveal any 
marked abnormality of the pancreas. After the second 
break, a 10-week   interruption, the serum lipase level 
was returned to normal and dasatinib was reintro-
duced at a further reduced dose of 20 mg/day taken 
in combination with Pancrelipase (Creon) capsules. 
At  a  subsequent  clinic  visit,  the  patient  presented 
with G2 pancreatitis and the treatment schedule and 
doses were maintained. In February 2010, the patient 
underwent a switch to alternate-day dasatinib at dos-
ages of 20 and 40 mg every other day. In March 2010, 
after 3 months of taking a lower dosage (20 mg/day) 
of dasatinib, the patient achieved a CCyR and his 
BCR-ABL/BCR showed a ratio of 0.1%. The mea-
surement of his transcript was repeated in August 
2010  and  confirmed  the  MMR  (BCR-ABL/BCR 
ratio = 0.018%). At that time, the patient had mild 
pancreatitis with serum lipase level and was scored 
as grade 1.
Discussion
Dasatinib  is  a  highly  effective  targeted  therapy 
in  patients  with  CML  who  are  unresponsive  to 
  imatinib,  or  as  an  alternative  where  imatinib  is 
poorly    tolerated. As  such,  it  provides  a  valuable 
therapeutic option for those patients who are at high 
risk for disease progression. Although dasatinib is 
generally well tolerated, serious toxicities can occur 
in some patients, even at a lower recommended dose 
of 80 mg/day, and can pose particular challenges 
to  clinicians  caring  for  this  subgroup  of  patients. 
Patients intolerant of dasatinib and other TKIs are 
unlike those resistant to therapy; they often suffer 
increased treatment interruptions and compromised 
therapeutic benefits. Therefore, to fit an individual’s 
unique profile, adjustment of dose on the basis of the 
patient`s response and tolerability is required. Our 
experience in this short case series demonstrate that 
dasatinib at a dose well below the minimum recom-
mended dosage has clinical activity associated with 
only minor toxicity in 4 dasatinib-intolerant patients 
who  had  previously  experienced    imatinib-related 
hematological  (3  cases)  and  non-hematological 
complications (1 case). At the time of initiation of Efficacy of dasatinib low doses in CML intolerant patients
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dasatinib therapy, two patients were in CP CML and 
the other two were in AP. All 4 patients had been 
initially treated with imatinib as a first-line therapy 
at either 400 mg/day or 600 mg/day and all but one 
developed hematological toxicities (Table 1). The 
same pre-existing   complications that occurred dur-
ing imatinib therapy were observed after crossover to 
dasatinib. It is possible that the complications mani-
fested in our patients during imatinib therapy may 
have increased the likelihood of these   abnormalities 
shortly after initiation of dasatinib. Alternatively, it 
is also possible that TKIs predisposed our patients to 
these AEs. In all patients, dasatinib, was the only sec-
ond generation TKIs available at that time, had to be 
reduced to a lower dose because of the dose-  limiting 
toxicity. The mean time to a CCyR in the first 3 
patients was 3 and 5.5 months; similar to durations 
of ,6 months that have been reported previously for 
standard doses.21,24 Administration of dasatinib at a 
reduced daily dose thus induces remissions in a sim-
ilar time frame compared with administration of a 
conventional dosage amount. Moreover, under con-
tinuous treatment with dasatinib under low dosage, 
there was progressive improvement of the platelet 
count in all of our first three patients, with progres-
sion to G1 thrombocytopenia (case 1 and 2) and 
complete normalization (case 3). Although the third 
patient developed G3 neutropenia with   dasatinib, it 
Table 1. patient characteristics and responses to treatment.
Case 1 Case 2 Case 3 Case 4
Age 31 46 69 58
Sex M M M M
CML phase Cp Ap* Ap Cp
Imatinib (mg/day) 400 400 600 400
§response to imatinib CHr pD Failure CHr
Imatinib  
associated Aes
G4  
thrombocytopenia
G3  
thrombocytopenia
G3  
thrombocytopenia
G4 
pancreatitis
Dasatinib starting  
dose (mg/day)
100 140 140 100
Dasatinib starting  
dose associated Aes
G4  
thrombocytopenia
G3  
thrombocytopenia
G3  
thrombocytopenia
G4 
pancreatitis
Mean daily doses  
of dasatinib until  
Ccyr (mg/day)
46.25 93.3 65.45 ♣23.3
Median daily doses  
of dasatinib until  
Ccyr (mg/day)
50 70 50 30
Time from dasatinib  
until CCyr (months)
4 3 5 ♣3
Intervention during 
dasatinib therapy
1st suspension for 
2 weeks, dasatinib 
reintroduction at 
80 mg/day 
2nd suspension for 
1 week, dasatinib 
reintroduction at 
50 mg/day
Dose reduced to 
70 mg/day
Dose reduced to 100, 
70, and 50 mg
1st suspension for 
2 weeks, dasatinib 
reintroduction at 
40 mg/day 
2nd suspension 
for 10 weeks, 
dasatinib 
reintroduction at 
20 mg/day
Dasatinib best  
response and duration  
of response (months)
MMr (13) CCyr (14) MMr (2) MMr (2)
Notes: *The patient progressed to Ap during imatinib treatment (after two months of treatment interruption the patient had platelets ,100.000 associated 
with left shift leukocytosis);  ♣The mean dose and time from dasatinib until CCyr were considered from the reintroduction of dasatinib at a dose of 
20 mg/day; §The remission status at the start of dasatinib therapy equally corresponds to imatinib response.
Abbreviations: M, Male; G, Grade; Cp, Chronic phase; Ap, Accelerated phase; pD, progression of disease; Aes, Adverse events; CHr, Complete 
hematologic response; CCyr, Complete cytogenetic remission; MMr, Major molecular remission.Serpa et al
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was easily   managed by the weekly   administration 
of  G-CSF.  The  myelosupression  can  occur  as  a 
result of a sudden hematopoiesis suppression that 
was maintained by Ph+ cells without equilibrium of 
the reappearance of the Ph- cells. Thus, we specu-
late that lower doses of dasatinib can correct this 
disequilibrium.
The fourth patient developed G4 pancreatitis after 
being initiated on imatinib mesylate and recurred with 
the same symptoms after switching to dasatinib even 
at the lower dose of 40 mg/day. The patient had no 
risk factors for pancreatitis and was taking no medi-
cations known to cause pancreatitis other than ima-
tinib. The reason why it was unlikely for this patient to 
develop pancreatitis due to CML is because the onset 
of  this  complication  appeared  during  the  imatinib 
treatment and then gradually improved upon suspen-
sion of therapy. De novo appearance of symptoms 
appeared after initiation of dasatinib.   Pancreatitis is 
an extremely rare adverse event which occurs after 
the use of TKIs.23,25–29 The pathophysiology of TKIs-
induced  pancreatitis  remains  speculative,  but  has 
been proposed by Plandari and colleagues26 to be due 
either to the inhibition of c-abl, which might interfere 
with the molecular mechanisms that regulate pancre-
atic cell death and thus induce pancreatic damage, or 
to the indirect effect of the drug on the release of cal-
cium from the intracellular acinar stores, which regu-
late exocrine pancreatic secretion, and may enhance 
the accumulation of fatty acid inside the pancreatic 
acinar cell, which disturbs exocytosis.
At the time of this report, three of the four patients 
we treated had achieved MMR. It is possible that the 
greater potency of BCR-ABL inhibition of dasatinib 
compared  to  imatinib  contributed  to  the  induction 
of remissions in our patients. Because of its greater 
potency (325-fold), it has previously been reported 
that exposure to low or subnanomolar concentrations 
of dasatinib is sufficient to commit cell lines express-
ing  BCR-ABL  to  apoptotic  cell  death.15,16  These 
results may help to explain the improved tolerability 
and efficacy observed in our patients.
An increasing number of investigators are explor-
ing the use of a lower dose intensity of dasatinib 
for  the  treatment  of  therapy  intolerant  patients. 
In one recent study, the frequency and significance 
of dose reductions and treatment holidays among 
280 patients treated with 2nd generation TKIs were 
retrospectively analyzed.30 The results revealed that 
176 (63%) of these patients required treatment inter-
ruptions and/or dose reduction at least once during 
therapy. The authors conclude that lower doses of 
dasatinib and nilotinib may potentially have similar 
efficacy in the therapy of CML as standard doses. 
In another small study, Bergeron et al31 investigated 
pleural and pulmonary complications in 40 patients 
who received dasatinib (70 mg twice daily) for ima-
tinib resistance or intolerance. Dasatinib treatment 
was interrupted in eight patients, either immediately 
after diagnosis of lung involvement (five patients), 
or  after  a  course  of  diuretics  (three  patients). 
After treatment holidays, lung abnormalities were 
resolved in all cases and did not recur in three out 
of four patients when dasatinib was reintroduced at 
a dose of 40 mg twice daily. In addition, Breccia 
et al32 treated a   34-year-old Ph+ CML female patient 
who  had  a  molecular  relapse  after  haploidentical 
BMT with chronic liver GVHD and was severely 
intolerant to both imatinib and dasatinib at a stan-
dard dose; she had a CMR to dasatinib at a reduced 
dose of 20 mg/day without serious adverse events. 
A recent case report published by Yamaguchi et al.33 
described a successful treatment of a 70-year-old 
man with CML who developed a megakaryoblas-
tic  crisis  concomitant  with  myelofibrosis  despite 
imatinib therapy with dasatinib at a starting dose of 
80 mg/day.
Despite the successful clinical response in these 
patients, conclusions drawn from this series should 
be  interpreted  with  caution  and  considered  tenta-
tive until experimental studies to define the mini-
mum  effective  dose  and  optimal  dosing  schedule 
for  dasatinib-  intolerant  patients  are  carried  out. 
  However, our series lend support to previous reports 
that showed a comparable efficacy of standard and 
low-dose dasatinib with very minor toxicities; thus, 
for patients intolerant to dasatinib at a standard dose, 
a gradual dose reduction may be tried before drug 
discontinuation.
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